ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2021
Effect of Aspirin on Activities of Daily Living Disability in Community-Dwelling Older Adults.
Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 19 citations in OpenAlex.
- Effect of aspirin on healthspan in community-dwelling older adults: the ASPirin in reducing events in the elderly study.Age and ageing · 2026Trial
- Effect of aspirin on grip strength and gait speed in community-dwelling older adults in the ASPirin in Reducing Events in the Elderly (ASPREE) Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2025Trial
- The association of allopurinol with persistent physical disability and frailty in a large community based older cohort.Journal of the American Geriatrics Society · 2023Trial
- The Effect of Low-Dose Aspirin on Frailty Phenotype and Frailty Index in Community-Dwelling Older Adults in the ASPirin in Reducing Events in the Elderly Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022Trial
- Validation of a Deficit-Accumulation Frailty Index in the ASPirin in Reducing Events in the Elderly Study and Its Predictive Capacity for Disability-Free Survival.The journals of gerontology. Series A, Biological sciences and medical sciences · 2022Trial
- Long-Term Aspirin Use and Self-Reported Walking Speed in Older Men: The Physicians' Health Study.The Journal of frailty & aging · 2022Trial
- The association between polypharmacy, frailty and disability-free survival in community-dwelling healthy older individuals.Archives of gerontology and geriatricsTrial
- How does disability contribute to deprivation in ageing process: a multidimensional analysis.Frontiers in public health · 2025Article
- Nut consumption and disability-free survival in community-dwelling older adults: a prospective cohort study.Age and ageing · 2024Article
- Aging and Inflammation.Cold Spring Harbor perspectives in medicine · 2024Review
- Epigenetic age acceleration and the risk of frailty, and persistent activities of daily living (ADL) disability.Age and ageing · 2024Article
- The Association between Frailty and Dementia-Free and Physical Disability-Free Survival in Community-Dwelling Older Adults.Gerontology · 2023Article
- The effect of depressive symptoms on disability-free survival in healthy older adults: A prospective cohort study.Acta psychiatrica Scandinavica · 2023Article
- The Association between Metabolic Syndrome, Frailty and Disability-Free Survival in Healthy Community-dwelling Older Adults.The journal of nutrition, health & aging · 2023Article
- Combination of gait speed and grip strength to predict cognitive decline and dementia.Alzheimer's & dementia (Amsterdam, Netherlands) · 2022Article
- Brain-predicted age difference is associated with cognitive processing in later-life.Neurobiology of aging · 2022Article
- Aspirin in the Modern Era of Cardiovascular Disease Prevention.Methodist DeBakey cardiovascular journal · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 11 institutions in 2 countries.
Funding
Abstract
backgroundCerebrovascular events, dementia, and cancer can contribute to physical disability with activities of daily living (ADL). It is unclear whether low-dose aspirin reduces this burden in aging populations. In a secondary analysis, we now examine aspirin's effects on incident and persistent ADL disability within a primary prevention aspirin trial in community-dwelling older adults.
methodsThe ASPREE (ASPirin in Reducing Events in the Elderly) trial of daily 100 mg aspirin versus placebo recruited 19 114 healthy adults aged 70+ years (65+ years if U.S. minority) in Australia and the United States. Six basic ADLs were assessed every 6 months. Incident ADL disability was defined as inability or severe difficulty with ≥1 ADL; persistence was confirmed if the same ADL disability remained after 6 months. Proportional hazards modeling compared time to incident or persistent ADL disability for aspirin versus placebo; death without prior disability was a competing risk.
resultsOver a median of 4.7 years, incident ADL disability was similar in those receiving aspirin (776/9525) and placebo (787/9589) with walking, bathing, dressing, and transferring the most commonly reported. Only 24% of incident ADL disability progressed to persistent. Persistent ADL disability was lower in the aspirin group (4.3 vs 5.3 events/1000 py; hazard ratio [HR] = 0.81, 95% confidence interval [CI]: 0.66-1.00), with bathing and dressing the most common ADL disabilities in both groups. Following persistent ADL disability, there were more deaths in the aspirin group (24 vs 12). DISCUSSION: Low-dose aspirin in initially healthy older people did not reduce the risk of incident ADL disability, although there was evidence of reduced persistent ADL disability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.